医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

广告
第一作者: Gambacorti-Passerini,C.
作者单位: Royal Brisbane Hospital, Herston, QLD, Australia [1] University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy [2] Ruijin Hospital, Shanghai, China [3] Christian Medical College, Vellore, Tamil Nadu, India [4] Pfizer, Cambridge, MA, United States [5] University of Groningen and University Medical Center Groningen, Groningen, Netherlands [6] Seoul St. Mary's Hospital, Seoul, South Korea [7] Hospital das Clínicas da Universidade Federal do Paraná, Paraná, Brazil [8] University of Texas MD Anderson Cancer Center, Houston, TX, United States [9] Hematology Research Center, Moscow, Russian Federation [10] Winship Cancer Institute of Emory University, Atlanta, GA, United States [11] Universit?tsklinikum Aachen, RWTH Aachen, Germany, Universit?tsklinikum Hamburg-Eppendorf, Hamburg [12] Jewish General Hospital, McGill University, Montreal, QC, Canada [13] University of Pavlov and Almazov Federal Heart, Blood, and Endocrinology Centre, St Petersburg [14] First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China [15] St. István and St. László Hospital, Budapest, Hungary [16] Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain [17] Pfizer Global Research and Development, Paris, France [18]
发布时间 2014-09-25
提交
  • 浏览0
American Journal of Hematology

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷